For children with severe hypertrophic cardiomyopathy caused by gain-of-function RAS/mitogen-activated protein kinase (MAPK) mutations (RASopathy), trametinib reduces mortality and morbidity.

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

1Hereditary Cancer Program, Catalan Institute of Oncology (ICO-IDIBELL), Hospitalet de Llobregat, Barcelona, Spain. 2Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), ...

A phase 2a trial of IMM-1-104 plus chemotherapy demonstrated efficacy and tolerability in first- and second-line pancreatic ...

MIAMI, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical ...

Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS/MAPK ...

Im­muneer­ing’s shares rock­et­ed in pre­mar­ket trad­ing on Tues­day on the back of pos­i­tive mid-stage da­ta for its MEK in­hibitor in pan­cre­at­ic can­cer, spark­ing plans to ...

Pasithea Therapeutics opens European clinical trial sites and completes initial dosing of cohort 4: Miami Thursday, January 16, 2025, 12:00 Hrs [IST] Pasithea Therapeutics Corp., ...

SpringWorks Therapeutics Inc . (NASDAQ:SWTX), a biotechnology company with a market capitalization of $2.66 billion focused ...

Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...

“The response rates emerging from both of our Phase 2a combination arms in first-line pancreatic cancer are comparable to one ...